^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JS019

    i
    Other names: JS019
    Associations

    News

    Trials
    Company:
    Beijing Eirene, Shanghai Junshi Biosci, Suzhou Kebo Ruijun Bio
    Drug class:
    CD39 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=72, Recruiting, Suzhou Kebo Ruijun Biotechnology Co., Ltd
    New P1 trial
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    JS019
    2years
    A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1, N=172, Recruiting, Suzhou Kebo Ruijun Biotechnology Co., Ltd
    New P1 trial
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    JS019